Posted by Michael Wonder on 06 Dec 2023
Secukinumab for the treatment of patients with moderate to severe hidradenitis suppurativa (final guidance)
6 December 2023 - NICE has published final evidence-based recommendations on the use of secukinumab (Cosentyx) for the treatment of adults with active moderate to severe hidradenitis suppurativa.
Secukinumab is recommended as an option for the treatment of adults with active moderate to severe hidradenitis suppurativa when it has not responded well enough to conventional systemic treatment, only if adalimumab is not suitable, did not work or has stopped working and Novartis provides secukinumab according to the commercial arrangements.
